Head-to-head
Mochi Health vs TMates
Compared on both medications across the eight dimensions this database records. They differ on 7 of those eight. TMates is cheaper on all-in tirzepatide at 10 mg/week, though on a flat-versus-tiered matchup the cheaper program can change further up the dose ladder.
The short answer
Mochi Health is $357 a month all-in for tirzepatide; TMates is $297. Over twelve months that is $4,284 against $2,004. Value Scores are 55.9 and 55.3 out of 100.
Tirzepatide
Plan pages: Mochi Health plans · TMates plans
At 10 mg/week, Mochi Health is $357 a month all-in and TMates is $297 — $60 apart, or $720 across a year. Over twelve months the totals are $4,284 (billed monthly) and $2,004 (prepaid term).
Mochi Health charges a flat $278 per month for tirzepatide at every dose from 2.5 to 15 mg per week, so titrating upward does not change what you pay.
TMates charges a flat $297 per month for tirzepatide at every dose from 2.5 to 15 mg per week, so titrating upward does not change what you pay. The company publishes no price at 5, 7.5, 12.5, 15 mg, so those doses are left blank rather than estimated.
| Dose | Mochi Health | Rank | TMates | Rank | Cheaper |
|---|---|---|---|---|---|
| 2.5 mg | $278 | 14/31 | $297 | 16/31 | Mochi Health by $19 |
| 5 mg | $278 | 7/17 | — | — | only Mochi Health publishes |
| 7.5 mg | $278 | 7/17 | — | — | only Mochi Health publishes |
| 10 mg | $278 | 8/27 | $297 | 12/27 | Mochi Health by $19 |
| 12.5 mg | $278 | 7/17 | — | — | only Mochi Health publishes |
| 15 mg | $278 | 7/17 | — | — | only Mochi Health publishes |
TMates is cheaper at every dose where both publish a price, so the lead does not change as you titrate.
Across the 27 programs this database can rank on tirzepatide, Mochi Health sits 17 of 27 on all-in monthly cost and TMates sits 10. There are 6 other programs priced between them. The field median is $339 and the floor is $169, so TMates is below the median and the other is above it. Mochi Health is $188 above the cheapest tirzepatide program on record. TMates is $128 above the cheapest tirzepatide program on record.
LillyDirect (Zepbound), the lowest FDA-approved tirzepatide channel here, is $449 a month — Mochi Health undercuts it by $92, TMates by $152. Compounded products are not FDA approved; insurance can reverse that comparison.
| Plan term | Mochi Health | TMates | Cheaper |
|---|---|---|---|
| Month to month | $278 | $297 | Mochi Health by $19 |
| 12-month term | — | $167 | only TMates publishes this term |
| Settled dose | Mochi Health | TMates | Difference |
|---|---|---|---|
| 2.5 mg | $4,284 | $3,564 | $720 apart |
| 5 mg | $4,284 | — | one side unpriced |
| 7.5 mg | $4,284 | — | one side unpriced |
| 10 mg | $4,284 | $3,564 | $720 apart |
| 12.5 mg | $4,284 | — | one side unpriced |
| 15 mg | $4,284 | — | one side unpriced |
Mochi Health publishes no rate for 3-month term, 6-month term, 12-month term; TMates publishes none for 3-month term, 6-month term. An unpublished term is not necessarily unavailable — it is unpriced in public, which you can only resolve by asking.
A titration year is not twelve months at the maintenance price. Stepping up roughly four weeks per dose before settling at 10 mg/week, the first twelve months work out to $4,284 on Mochi Health and $3,564 on TMates. The ramp is cheaper than the settled rate on whichever program prices by dose, which is why a first-year quote and a steady-state quote are not the same number.
That calculation is partial: TMates publishes no price at 2 of them, so the maintenance rate stands in for the missing steps rather than a number the company has stated.
Value Scores are 55.9 for Mochi Health and 55.3 for TMates, against a tirzepatide category floor of $169. Mochi Health leads by 0.6 points, driven mostly by price.
| Program | Price /70 | Evidence /15 | Dose /10 | Membership /5 | Total /100 |
|---|---|---|---|---|---|
| Mochi Health | 33.1 | 12.8 | 10 | 0 | 55.9 |
| TMates | 39.8 | 10.5 | 0 | 5 | 55.3 |
Semaglutide
Plan pages: Mochi Health plans · TMates plans
At 2.4 mg/week, Mochi Health is $257 a month all-in and TMates is $249 — $8 apart, or $96 across a year. Over twelve months the totals are $3,084 (billed monthly) and $1,896 (prepaid term).
Mochi Health charges a flat $178 per month for semaglutide at every dose from 0.25 to 2.4 mg per week, so titrating upward does not change what you pay.
TMates charges a flat $249 per month for semaglutide at every dose from 0.25 to 2.4 mg per week, so titrating upward does not change what you pay. The company publishes no price at 0.5, 1, 1.7 mg, so those doses are left blank rather than estimated.
TMates is cheaper at every dose where both publish a price, so the lead does not change as you titrate.
Value Scores are 57.9 for Mochi Health and 51.8 for TMates, against a semaglutide category floor of $129. Mochi Health leads by 6.1 points, and the margin comes from structure rather than price alone.
Where the two programs differ
All-in monthly
TMates is cheaper month to month — $297 against $357, a gap of $60 every month, or $720 across a year if both rates hold.
Cancellation terms
Cancellation differs: Mochi Health states Cancel anytime before renewal, while TMates states Per provider terms. Read this next to the twelve-month figures — a prepaid discount and a restrictive refund policy are the same decision.
Commitment
Mochi Health asks for Month-to-month; TMates asks for 12-month plan or month-to-month; substantial difference in rates. This is the dimension most likely to change which program is actually cheaper for you, because the lowest rates on both sides are usually attached to the longest terms.
Dose policy
Mochi Health charges one price at every dose; TMates prices by dose. That difference usually matters more than the headline gap, because the tiered program's advertised figure describes the dose you start on, not the dose you settle at.
Evidence status
The two prices are not equally well evidenced. Mochi Health's figure is provider-stated and TMates's is reported. Mochi Health rests on the stronger of the two, and the Value Score below reflects that — evidence quality is worth fifteen points and is not a tiebreaker we apply after the fact.
Membership fee
Mochi Health charges a membership of $79 a month on top of the medication. That is already folded into the all-in figures above — it is broken out here because a membership is a recurring charge that continues even in a month you skip a shipment.
Twelve-month cost
Over twelve months the totals are $4,284 for Mochi Health and $2,004 for TMates. TMates is lower by $2,280 — a figure worth checking against the cancellation terms below, because a prepaid year is only cheaper if you stay on it.
Shipping
Shipping is handled the same way by both — included in the quoted price.
What each record says
Mochi Health Official site
Mochi separates a $79/month clinical membership ($39 first month in some states) from flat medication pricing — $99/month semaglutide at any dose and $199/month tirzepatide at any dose — which makes its all-in cost easy to compute and its structure one of the most transparent in the category.
It names its compounding pharmacy — Partner 503A/503B pharmacies, recorded as Partner network — which can be checked against state board licensing and FDA inspection records before you order; commitment terms are Month-to-month; cancellation is Cancel anytime before renewal; availability is stated as ~50 states.
Evidence: provider-stated — taken from the provider's own published pages; checkout capture pending, captured . Source — joinmochi.com pricing + FAQ captures 2026-07-20 and 2026-08-05
Watch: Advertising leads with the medication price; the $79 membership is the number people miss. Eli Lilly named Mochi in 2025 personalized-dosing litigation; the company continues to operate.
TMates Official site
TMates is a compounded GLP-1 telehealth service that includes medication and visits in one bundled monthly price. It offers both semaglutide and tirzepatide, with a 12-month plan that brings tirzepatide to $167/mo — the lowest committed-plan figure for tirz outside of bmiMD and NexLife.
It does not publicly name its compounding pharmacy; the record shows Partner 503A pharmacy (not publicly named), so who actually makes the medication cannot be independently verified; commitment terms are 12-month plan or month-to-month; substantial difference in rates; cancellation is Per provider terms; availability is stated as Confirm at intake.
Evidence: reported — sourced from dated third-party reporting; first-party capture pending, captured . Source — rangeyourself.com, capture 2026-07-14
Watch: The $158/mo (sema) and $167/mo (tirz) headline figures are 12-month plan rates; month-to-month is $249 (sema) and $297 (tirz) — some of the widest start-to-commitment spreads in the index. Reported status from RangeYourself 2026-07-14 verification.
What neither record tells you
Mochi Health does not publish
- no published twelve-month tirzepatide rate
- no published twelve-month semaglutide rate
- no state-by-state availability list — it says ~50 states
TMates does not publish
- no tirzepatide price at 5, 7.5, 12.5, 15 mg per week
- no semaglutide price at 0.5, 1, 1.7 mg per week
- no named compounding pharmacy
- no state-by-state availability list — it says Confirm at intake
- no specific cancellation or refund terms
Ask Mochi Health and TMates for each of those in writing before enrolling. A gap is not evidence of a problem; it does mean nothing can be checked against it.
What would change this answer
Evidence may be upgraded. TMates carries a price we have not captured at checkout. A capture would move the evidence term and could reorder these two without any price changing.
Prepaid terms move the annual figures. TMates publishes a twelve-month rate of $167 a month against $297 month-to-month. Read those next to the cancellation terms, not the monthly rate.
Which one suits which reader
On the lowest standing monthly rate for tirzepatide, TMates Official site wins this matchup. If you expect to titrate to the top of the ladder, mochi health's flat pricing is worth more than the headline gap suggests; if you want to be able to pause without still paying, tmates carries no membership; and if you would rather trust a better-evidenced number, mochi health's price rests on stronger provenance.
Both figures should be checked at the provider's own checkout before you pay. Mochi Health's tirzepatide price is provider-stated as of 2026-08-05; TMates's is reported as of 2026-07-14.
Questions
Is Mochi Health or TMates cheaper for tirzepatide?
TMates is cheaper on all-in monthly cost at 10 mg/week: $297 against $357, a difference of $60 a month. All-in means the medication plus every mandatory recurring fee.
What is the twelve-month cost of Mochi Health versus TMates?
Mochi Health works out to $4,284 across twelve months and TMates to $2,004, on the plan terms each publishes.
Does Mochi Health or TMates raise the price as the dose goes up?
Mochi Health: no, it charges one flat rate at every dose. TMates: yes, it prices by dose. Where one program is flat and the other is tiered, the cheaper of the two can change as you titrate upward.
How many ways do Mochi Health and TMates differ?
7 of the eight dimensions this site records: all-in monthly, twelve-month cost, dose policy, membership, shipping, commitment, cancellation terms and evidence status.
Which of Mochi Health and TMates names its pharmacy?
Mochi Health does — Partner 503A/503B pharmacies. TMates does not, recording only Partner 503A pharmacy (not publicly named), so who makes its medication cannot be independently verified.
How well evidenced are the Mochi Health and TMates prices?
Mochi Health's tirzepatide figure is provider-stated — taken from the provider's own published pages; checkout capture pending — captured 2026-08-05. TMates's is reported, captured 2026-07-14. Evidence status is worth fifteen points in the Value Score, so it is priced in rather than mentioned as an aside.
Which is cheaper for semaglutide?
TMates, at $249 a month all-in against $257 at 2.4 mg/week. The two programs do not necessarily lead on both medications.
Official sources: Mochi Health official site · TMates official site. Compounded tirzepatide and semaglutide are not FDA-approved products.